However, when considering the involvement of NLRP3 inflammasome activation in ALS (Deora et al., 2020), more studies focusing on IL-18 may provide better insights if blocking inflammasomes may be a beneficial strategy in ALS treatment. This evidence concerns the gene IL18 and amyotrophic lateral sclerosis.